4 completed, 3 terminated, 1 recruiting, 1 unknown. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Terminated 3, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
Follow serabelisib: new trials by email Literature Review of serabelisib trials Research Report on serabelisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Faeth Therapeutics | 32 | 2026-04-22 | 2026-11-18 |
| Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Serabelisib, Insulin Suppressing Diet, Nab paclitaxel - Advanced Solid Tumor, PIK3CA Mutation | Phase 1 | Terminated | Faeth Therapeutics | 34 | 2022-04-22 | 2026-04-30 |
| A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Serabelisib, Canagliflozin 300mg - Breast Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Unknown | Petra Pharma | 60 | 2020-09-01 | 2020-05-21 |
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors paclitaxel, TAK-228, TAK-117 - Advanced Solid Tumor | Phase 1 | Completed | Avera McKennan Hospital & University Health Center | 19 | 2017-07-06 | 2024-07-26 |
| A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants TAK-117, Lansoprazole - Neoplasm, Advanced or Metastatic | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 54 | 2016-01-08 | 2018-01-08 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma MLN1117, TAK-659, Alisertib - Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 32 | 2015-10-15 | 2019-09-20 |
| Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer Docetaxel, TAK-117 - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 14 | 2015-06-03 | 2018-02-07 |
| A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies TAK-228, TAK-117 - Advanced Nonhematologic Malignancies | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 101 | 2013-06-28 | 2019-10-30 |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer TAK-117 - Metastatic Solid Tumors | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 125 | 2011-10-01 | 2017-03-09 |
Breast Neoplasms (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Millennium Pharmaceuticals, Inc. (5) · Faeth Therapeutics (2) · Avera McKennan Hospital & University Health Center (1) · Petra Pharma (1)
United States (7) · Spain (3) · United Kingdom (2) · Canada (1) · Netherlands (1)
Albert Yu, MD (1) · Casey Williams, PharmD (1) · Vicky Makker (1)
2014 (1), 2015 (1)